Tasly

Tasly is a Chinese pharmaceutical and health-care brand headquartered in Tianjin. Founded in 1994 by Yan Xijun, it began with the modernization of traditional Chinese medicine and developed into a diversified life-and-health enterprise covering modern traditional Chinese medicines, biopharmaceuticals, chemical drugs, health products, medical services and selected investment businesses. Its principal listed operating company is Tasly Pharmaceutical Group Co., Ltd., which trades on the Shanghai Stock Exchange under ticker 600535.SS. The company’s identity is closely associated with the industrialization of traditional Chinese medicine. Rather than positioning TCM solely as a heritage or wellness category, Tasly has emphasized standardized raw materials, controlled manufacturing, dosage-form innovation, clinical research, quality systems and international regulatory work. Its best-known product is Compound Danshen Dripping Pills, marketed internationally under the Dantonic brand. The formulation is used in the cardiovascular field and has been the subject of a long-running development and regulatory program in the United States. Tasly’s modern-TCM portfolio also includes Yangxue Qingnao products, Qishen Yiqi Dripping Pills and Yiqi Fumai for Injection. Tasly’s pharmaceutical portfolio extends beyond TCM. The group has developed or commercialized biopharmaceuticals such as recombinant human prourokinase for injection, a thrombolytic product, and chemical medicines including temozolomide, eszopiclone and tadalafil. Company materials describe a therapeutic focus on cardiovascular and metabolic disease, digestive disease, oncology and immunology, and neurological or psychiatric conditions. Its research model combines internal discovery, cooperative development, product licensing, acquisitions and commercialization partnerships. Internationalization has been a recurring strategic theme. Tasly established Tasly Pharmaceuticals, Inc. in the United States in 2006 to support clinical research, regulatory affairs, technical cooperation and overseas business development. The group has also pursued international research and commercialization arrangements, including a 2015 cooperation agreement concerning T89, the development code for Compound Danshen Dripping Pills, and a proposed consumer-health joint venture with Herbalife announced in 2017. The company’s international activities are intended to connect Chinese medicine research and manufacturing capabilities with foreign regulatory, scientific and distribution networks. The wider Tasly group has historically operated beyond prescription and hospital medicines. Its broader health platform has included functional foods, health-management services, medical and rehabilitation services, botanical products, tea-based products, mineral water and other consumer-health businesses. The group has also owned or invested in non-pharmaceutical businesses, including Guotai liquor and Yunnan tea operations. This broader structure is reflected in Tasly’s use of concepts such as “great health,” digital health and intelligent health services, although the Shanghai-listed pharmaceutical company remains the core public pharmaceutical asset. A significant ownership transition occurred in 2025. China Resources Sanjiu acquired a 28% interest from Tasly’s former controlling shareholders, and the transaction completed on March 27, 2025. Tasly consequently became a non-wholly-owned subsidiary of China Resources Sanjiu and, through it, part of the China Resources group. The transaction also produced changes to the listed company’s board and senior management. Following the change, Cai Jinyong became chairman and general manager, while Xi Kai became a worker director and general manager of the company’s operating structure. Tasly’s present positioning therefore combines three elements: a listed pharmaceutical manufacturer, a recognized modern-TCM platform and a broader life-and-health group undergoing integra…

Tasly was established in Tianjin in 1994 by Yan Xijun. Its early development centered on the idea that traditional Chinese medicine could be industrialized through modern pharmaceutical technology, standardized production and evidence-oriented research. The company’s initial identity was therefore different from that of a conventional herbal-products seller: it sought to create reproducible dosage forms and scalable manufacturing systems for TCM-derived medicines. Compound Danshen Dripping Pills became the company’s signature product and a major vehicle for its modernization strategy. The dripping-pill dosage form helped Tasly build a recognizable commercial franchise in cardiovascular medicine while also giving the company a product around which it could organize manufacturing technology, quality control, clinical research and international regulatory work. Tasly later developed a broader modern-TCM portfolio that included Yangxue Qingnao products, Qishen Yiqi Dripping Pills and Yiqi Fumai for Injection. Tasly expanded its corporate scope during the late 1990s and early 2000s. The group entered additional consumer and health-related businesses, acquired or established operations outside its core pharmaceutical activity and developed a more diversified holding-company structure. In 2002, the pharmaceutical company was listed on the Shanghai Stock Exchange. The listing supplied a public-capital platform for manufacturing expansion, research facilities and further product development. The company’s internationalization effort became more visible in the 2000s. Tasly Pharmaceuticals, Inc. was established in Rockville, Maryland, in 2006. The United States entity was designed to support clinical research, regulatory submissions, scientific evaluation, technical cooperation, brand promotion and overseas market development. Compound Danshen Dripping Pills entered an FDA-centered development pathway, receiving an investigational new drug-related milestone in 1997, passing Phase II clinical trials in 2010 and later reaching Phase III development. In 2015, Tasly also agreed to cooperate with Arbor Pharmaceuticals on the research and marketing of T89 in the United States. Alongside modern TCM, Tasly built a biomedical and chemical-drug platform. Tasly Bio-pharmaceutical Co., Ltd. was founded in 2001 and developed capabilities spanning research, manufacturing and commercialization. The group’s products and pipeline came to include recombinant human prourokinase for injection, chemical medicines such as temozolomide, eszopiclone and tadalafil, and additional candidates in cardiovascular, oncology, autoimmune, digestive and metabolic fields. The company described its research model as a combination of independent research, cooperative research, product introduction, acquisition and commercialization investment. Tasly’s production and research infrastructure expanded during the 2010s. The group began construction of its Huai’an biomedical industrial park in 2010, established or developed additional manufacturing and research sites, and received approvals connected with a national key laboratory for innovative Chinese medicine and a state-local joint engineering laboratory. The company presented these facilities as part of a broader effort to connect formulation science, raw-material traceability, intelligent manufacturing, clinical evidence and international regulatory requirements. The group also pursued a broader “great health” strategy. Its activities extended into functional foods, botanical materials, tea products, mineral water, health management, medical services, rehabilitation and other consumer-health categories. Guotai liquor and Yunnan tea became notable non-pharmaceutical businesses within the wider Tasly ecosystem. This diversification created a corporate house broader than the listed pharmaceutical company itself, while the pharmaceutical business remained the group’s most important public-market identity. Tasly’s development was accompanied by controversy. In 2009, pharmacologist Li Lianda publicly questioned the safety of a key Tasly product. Tasly brought a lawsuit against Li in 2013, arguing that the allegation was unfounded and influenced by his relationships with Guangzhou Pharmaceutical, a competitor. In September 2014, the Tianjin High People’s Court ruled in Tasly’s favor and ordered Li to apologize and pay CNY 300,000. The episode remains the principal scandal or legal controversy associated with the Tasly article in English-language reference material. In 2017, Tasly and Herbalife announced plans for a United States joint venture, HT Innovations LP. The proposed venture was intended to combine Tasly’s formulations, patents and clinical work with Herbalife’s scientific, regulatory and distribution capabilities. The announcement illustrated Tasly’s interest in international consumer health, although the available reference material does not establish that the proposed structure became a major operating business. A major structural change came in 2024 and 2025. China Resources Sanjiu agreed to acquire a 28% stake in Tasly Pharmaceutical from the former controlling shareholders. The share transfer was completed on March 27, 2025, making Tasly a non-wholly-owned subsidiary of China Resources Sanjiu and, through the China Resources group, part of a large state-owned pharmaceutical ecosystem. Former controlling shareholders and several directors departed, while a new board and senior-management team was appointed. Cai Jinyong became chairman and general manager, and the company’s operating priorities became more closely integrated with China Resources Sanjiu’s pharmaceutical platform. In its current form, Tasly combines a long-established modern-TCM franchise with biopharmaceutical and chemical-drug capabilities. It continues to emphasize cardiovascular and metabolic disease, digestive disease, oncology and immunology, and neurological or psychiatric conditions. Its corporate narrative now places greater weight on full-course health management, digital empowerment, intelligent manufacturing and integration with the wider China Resources health-care portfolio. Tasly’s history is consequently one of transformation: from a Tianjin modern-TCM pioneer into a listed, diversified pharmaceutical company and ultimately a controlled subsidiary within a major state-owned health-care group.

1. 2025China Resources Sanjiu became Tasly’s controlling shareholder

   A 28% share transfer completed on March 27, 2025, making Tasly a non-wholly-owned subsidiary of China Resources Sanjiu and changing its board and senior management.

   Source
2. 2024Tasly celebrated its thirtieth anniversary

   The group marked three decades of operations and presented its evolution toward a broader life-and-health platform.

   Source
3. 2017Tasly and Herbalife announced a proposed joint venture

   The proposed HT Innovations LP was intended to develop and commercialize consumer-health products for international markets.

   Source
4. 2016Compound Danshen Dripping Pills passed FDA Phase III trials

   Tasly reported completion of Phase III clinical development for the product in the FDA-centered United States program.

   Source
5. 2015Tasly established a major innovative-TCM research platform

   The company received approvals connected with a national key laboratory and a state-local joint engineering laboratory focused on innovative Chinese medicine.

   Source
6. 2015Tasly and Arbor Pharmaceuticals agreed to cooperate on T89

   The parties agreed to cooperate on research and marketing of Compound Danshen Dripping Pills in the United States.

   Source
7. 2014Tasly expanded North American operations

   The company formally launched North American operations as part of its internationalization strategy.

   Source
8. 2011Recombinant human prourokinase was launched

   Tasly launched rhPro-UK, a biological thrombolytic product described by the company as a national Class I new medicine.

   Source
9. 2010Compound Danshen Dripping Pills passed FDA Phase II trials

   Tasly reported completion of Phase II clinical development for its leading modern-TCM product in the United States.

   Source
10. 2006Tasly Pharmaceuticals, Inc. was established in the United States

    The Rockville, Maryland subsidiary was created to support overseas clinical research, regulatory affairs, technical cooperation and market development.

    Source
11. 2002Tasly was listed on the Shanghai Stock Exchange

    The listed pharmaceutical company began trading on August 23, 2002, under stock code 600535.

    Source
12. 2001Tasly Bio-pharmaceutical was established

    The group created a dedicated biopharmaceutical company to integrate biological-drug research, manufacturing and commercialization.

    Source
13. 1997Compound Danshen Dripping Pills entered the FDA development pathway

    The product received approval for an FDA investigational new drug application as a therapeutic medicine, beginning a long international development program.

    Source
14. 1994Tasly was founded in Tianjin

    Yan Xijun established Tasly, initially focusing the business on the modernization and industrial production of traditional Chinese medicine.

    Source

A modern-TCM and biomedical pharmaceutical platform that combines standardized traditional Chinese medicine, innovative biopharmaceuticals, chemical drugs and integrated health services.

• Compound Danshen Dripping Pills (Dantonic; T89)Modern traditional Chinese medicine

  Tasly’s signature product is a dripping-pill formulation derived from traditional Chinese medicine and positioned primarily for cardiovascular indications. It has served as the company’s main internationalization vehicle, with an FDA-centered clinical and regulatory program, multiple stages of clinical development and cooperation with overseas pharmaceutical companies. The product is also marketed internationally under the Dantonic name and is central to Tasly’s reputation as a modern-TCM manufacturer.

• Yangxue Qingnao Granules and PillsModern traditional Chinese medicine

  Yangxue Qingnao is part of Tasly’s modernized Chinese-medicine portfolio. The company markets the granule and pill forms within its neurological and circulation-related product offerings. The line illustrates Tasly’s approach of converting classical or traditional therapeutic concepts into standardized industrial dosage forms for domestic pharmaceutical distribution.

• Qishen Yiqi Dripping PillsModern traditional Chinese medicine

  Qishen Yiqi Dripping Pills are included in Tasly’s cardiovascular modern-TCM portfolio. The product uses the group’s characteristic dripping-pill technology and forms part of the company’s effort to build differentiated products around cardiovascular and metabolic disease. It is one of the principal modern Chinese formulae cited in Tasly’s corporate product materials.

• Yiqi Fumai for InjectionModern traditional Chinese medicine

  Yiqi Fumai for Injection, supplied in a freeze-dried formulation, is one of Tasly’s modernized Chinese-medicine products for hospital and clinical use. Its inclusion alongside dripping pills demonstrates the company’s broader dosage-form capabilities, extending from oral and rapidly dissolving products to injectable preparations.

• Recombinant human prourokinase for injection (rhPro-UK)Biopharmaceutical2011

  Recombinant human prourokinase is a biological thrombolytic medicine developed and commercialized by Tasly. The company describes it as a national Class I biological new medicine and launched it in 2011. It represents Tasly’s move beyond traditional Chinese medicine into recombinant biologics and cardiovascular emergency treatment.

• TemozolomideChemical pharmaceutical

  Temozolomide is a chemical oncology medicine included in Tasly’s pharmaceutical portfolio. Its presence gives the company exposure to conventional small-molecule cancer treatment in addition to its modern-TCM and biological-drug businesses. Tasly identifies oncology as one of its principal therapeutic priorities.

• Eszopiclone tabletsChemical pharmaceutical

  Eszopiclone tablets are part of Tasly’s chemical-drug portfolio and support the company’s activity in central-nervous-system and sleep-related treatment categories. The product is cited by Tasly as an example of its ability to commercialize conventional chemical medicines alongside innovative TCM and biopharmaceutical products.

• TadalafilChemical pharmaceutical

  Tadalafil is another chemical medicine cited in Tasly’s corporate product materials. Its inclusion reflects the breadth of the listed pharmaceutical company’s portfolio beyond the cardiovascular and traditional-medicine products most closely associated with the Tasly brand.

• Deepure biological tea productsConsumer health product

  Deepure is associated with Tasly’s broader health and lifestyle activities, particularly tea-based consumer products and biological tea processing. The business links botanical raw materials, processing technology and wellness-oriented consumption, illustrating the wider group’s “great health” strategy beyond prescription medicines.

• C-Cell Vitality mineral waterConsumer health product

  C-Cell Vitality is a mineral-water product described in Tasly group materials as being sourced from underground springs in Jilin and marketed with technology and mineral-content claims. It belongs to the broader Tasly Holding Group rather than the core listed pharmaceutical portfolio.

• 2024Tasly 30th anniversary program

  China · International

  Tasly marked its thirtieth anniversary with internal and public-facing activities emphasizing its development from a modern-TCM enterprise into a diversified life-and-health group.

  Outcome. The anniversary reinforced the group’s corporate narrative around innovation, intelligent manufacturing, globalization and integrated health.

  Source
• 2024ESG and intelligent-manufacturing positioning

  China

  Tasly promoted environmental management, social responsibility, governance and intelligent manufacturing as part of its corporate reputation and industrial-development program.

  Outcome. The company reported ESG-oriented recognition at the 2024 China International Fair for Trade in Services and continued to present smart manufacturing as a strategic capability.

  Source
• 2017HT Innovations LP with Herbalife

  United States · International

  Tasly and Herbalife announced a proposed joint venture intended to develop and commercialize consumer-health products. The plan was designed to combine Tasly’s formulations, patents and clinical research with Herbalife’s scientific, regulatory and global distributor network.

  Outcome. The available announcement describes a proposed structure and expected regulatory approvals but does not establish a significant subsequent operating outcome.

  Source
• 2015T89 international development and Arbor cooperation

  United States · North America

  Tasly used Compound Danshen Dripping Pills’ international development code, T89, as a platform for overseas research and commercialization. A cooperation agreement with Arbor Pharmaceuticals supported research and marketing planning in the United States.

  Outcome. Tasly subsequently reported completion of Phase III clinical development for Compound Danshen Dripping Pills in 2016, although the reference materials do not establish final United States approval.

  Source

• 2025Accept China Resources Sanjiu as controlling shareholderM&A

  Tasly’s former controlling shareholders agreed to transfer 28% of the listed pharmaceutical company to China Resources Sanjiu. The transaction formed part of a broader China Resources pharmaceutical consolidation strategy.

  What changed. The share transfer was completed on March 27, 2025. China Resources Sanjiu became the controlling shareholder, and Tasly became a non-wholly-owned subsidiary. The transaction was associated with changes to the board, supervisory bodies and senior management.

  Aftermath. Cai Jinyong became chairman and general manager, while China Resources became Tasly’s ultimate controlling system. The listed company retained its Shanghai listing and ticker 600535.SS.

  Consideration for the transferred 28% stake. CNY 6,073,803,149.04 after adjustment; originally CNY 6,211,844,129.70 before specified dividend-related adjustments (Transaction announced in 2024; completed March 27, 2025)

  Source
• 2017Propose a joint venture with HerbalifeM&A

  Tasly sought to pair its modern-TCM formulations, patents and clinical research with Herbalife’s scientific, regulatory and international distribution capabilities.

  What changed. The parties announced plans for HT Innovations LP in the United States to develop and commercialize consumer-health products.

  Aftermath. The announcement described the venture as subject to regulatory approval. The available sources do not provide sufficient evidence to characterize the venture’s long-term operating results.

  Source
• 2015Deepen international development of T89Strategy

  Compound Danshen Dripping Pills was Tasly’s leading modern-TCM product and the principal vehicle for entering international pharmaceutical markets.

  What changed. Tasly cooperated with Arbor Pharmaceuticals on research and marketing of T89 in the United States and continued the product’s FDA-centered clinical program.

  Aftermath. Tasly reported that the product passed Phase III clinical trials in 2016. The available materials do not confirm final United States marketing authorization.

  Source
• 2006Establish a United States international platformStrategy

  Tasly needed a dedicated overseas structure to manage clinical research, regulatory interaction, technical cooperation and international business development.

  What changed. The group established Tasly Pharmaceuticals, Inc. in Rockville, Maryland.

  Aftermath. The subsidiary became Tasly’s stated overseas headquarters and a platform for internationalization of its pharmaceutical portfolio.

  Source
• 2002Use public-market capital to scale the pharmaceutical businessStrategy

  Tasly was expanding manufacturing and research capabilities around modern TCM and needed a listed corporate platform.

  What changed. Tasly Pharmaceutical Group listed on the Shanghai Stock Exchange on August 23, 2002, under code 600535.

  Aftermath. The listing established Tasly as a public pharmaceutical company and provided the foundation for subsequent investment, product development and corporate expansion.

  Source

• 2014Litigation over safety criticism of a Tasly productControversy

  Pharmacologist Li Lianda criticized the safety of a key Tasly product in 2009. Tasly sued him in 2013, alleging that the criticism was baseless and influenced by financial and employment relationships with Guangzhou Pharmaceutical. In September 2014, the Tianjin High People’s Court ruled in Tasly’s favor and ordered Li to apologize and pay CNY 300,000 in compensation.

  Source

• 2025Tasly Pharmaceutical became a non-wholly-owned subsidiary of China Resources Sanjiu

  The transfer of 28% of Tasly Pharmaceutical’s shares to China Resources Sanjiu was completed on March 27, 2025. The transaction changed the listed company’s controlling shareholder and ultimate controller and led to board and senior-management changes.

  M&ALeadership change
  Source
• 2025Tasly reported 2024 revenue of CNY 8.498 billion

  Tasly’s 2024 company materials reported revenue of CNY 8.498 billion and non-IFRS net profit of CNY 1.069 billion for the 2024 reporting period.

  Other
  Source
• 2024Tasly marked its 30th anniversary

  The group held anniversary activities in May 2024, presenting the milestone as a review of its development from a modern-TCM enterprise into a broader life-and-health group.

  CampaignOther
  Source
• 2024Tasly received ESG-oriented management recognition at CIFTIS

  Tasly Pharma Group was recognized at the 2024 China International Fair for Trade in Services for its environmental, social and governance management practices.

  Other
  Source
• 2024Tasly was included in 2024 private-enterprise rankings

  Tasly reported inclusion in 2024 national private-business and private-manufacturer rankings, reflecting the broader group’s continuing visibility in China’s private-sector economy.

  Other
  Source
• 2017Tasly and Herbalife announced a proposed United States joint venture

  Tasly and Herbalife announced plans for HT Innovations LP, intended to develop and commercialize consumer-health products using Tasly formulations and research alongside Herbalife’s scientific, regulatory and international distribution capabilities.

  M&AOther
  Source
• 2016Compound Danshen Dripping Pills completed FDA Phase III clinical trials

  Tasly reported that Compound Danshen Dripping Pills had passed Phase III clinical trials in the United States development program.

  Product generation
  Source
• 2015Tasly and Arbor Pharmaceuticals agreed to cooperate on T89

  Tasly entered into a cooperation arrangement with United States-based Arbor Pharmaceuticals concerning research and marketing of T89, the international development designation for Compound Danshen Dripping Pills.

  Product launch
  Source
• 2014Tasly expanded its North American operations

  Tasly officially launched operations in North America, building on its United States regulatory, clinical and business-development platform.

  Other
  Source
• 2011Tasly’s recombinant human prourokinase product was launched

  Tasly released recombinant human prourokinase for injection, described by the company as a national Class I biological thrombolytic medicine.

  Product launch
  Source
• 2002Tasly was listed on the Shanghai Stock Exchange

  Tasly’s listed pharmaceutical company began trading on the Shanghai Stock Exchange on August 23, 2002, under stock code 600535.

  Other
  Source

1. Tasly, English Wikipedia article
2. Tasly Holding Group company profile and history
3. Tasly Pharmaceutical Group company profile
4. Tasly Group leadership and founder profile
5. Tasly Holding Group member companies and international platform
6. China Resources Pharmaceutical Group announcement on completion of Tasly acquisition
7. Tasly 2025 interim report
8. Herbalife announcement on proposed HT Innovations joint venture
9. China Resources Sanjiu transaction materials
10. Compound Danshen Dripping Pills entered the FDA development pathway
11. Tasly celebrated its thirtieth anniversary